跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN98539585
ISRCTN98539585进行中（未招募）3 期

An open-label extension trial to evaluate the long-term safety of KVD900, an oral plasma kallikrein inhibitor, for on-demand treatment of angioedema attacks in adolescent and adult patients with hereditary angioedema type I or II

KalVista Pharmaceuticals Ltd0 个研究点目标入组 145 人开始时间: 2022年11月28日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
3 期
状态
进行中（未招募）
入组人数
145
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •Current inclusion criteria as of 02/04/2024:
  • •Rollover Patients:
  • •1R. Randomized in the KVD900-301 trial.
  • •Non-Rollover Patients:
  • •1NR) Confirmed diagnosis of HAE type I or II at any time in the medical history:
  • •a) Documented clinical history consistent with HAE (sc or mucosal, nonpruritic swelling episodes without accompanying urticaria) AND EITHER
  • •i) Diagnostic testing results obtained prior to randomization that confirms HAE type I or II: C1-INH functional level <40% of the normal level. Patients with functional C1-INH level 40-50% of the normal level may be enrolled if they also have a C4 level below the normal range. Testing may be obtained from central or local laboratories or obtained from documented historical testing results. Patients may be retested at any time prior to randomization if results are incongruent with clinical history or believed by the Investigator to be confounded by recent prophylactic or therapeutic C1-INH use, OR
  • •ii) Documented genetic results that confirm known mutations for HAE type I or II.
  • •2NR) Patient has had at least 2 documented HAE attacks within 3 months prior to the Enrollment Visit.
  • •3NR) If a patient is receiving long-term prophylactic treatment with one of the protocol-allowed therapies, they must have been on a stable dose and regimen for at least 3 months prior to the Enrollment Visit.
  • •All Patients (AP):
  • •1AP) Male or female patients 12 years of age and older.
  • •2AP) Patients must meet one of the following contraception requirements as follows:
  • •a) Female patients who are fertile and heterosexually active must agree to use contraception from the Enrollment Visit until the EOS or Early Termination (ET) Visit. Acceptable methods of contraception include one or more of the following:
  • •i) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable/implantable (hormonal contraception that contains estrogen including ethinylestradiol is excluded per Exclusion Criterion 5NR.
  • •ii) Intrauterine device.
  • •iii) Intrauterine hormone–releasing system. iv) Bilateral tubal occlusion.
  • •v) Vasectomized partner (provided that the partner is the sole heterosexual partner of the female patient of childbearing potential and that the vasectomized partner has received a medical assessment of surgical success).
  • •vi) Male or female condom.
  • •vii) Cap, diaphragm, or sponge with spermicide.
  • •b) Patients who are not fertile or not heterosexually active, as defined below, do not require contraception. If the patient’s status changes during the course of the trial, they will be required to meet the requirements specified in Inclusion Criterion 2AP.
  • •i) Female patients who refrain from heterosexual intercourse during the trial if the reliability of the heterosexual abstinence has been evaluated in relation to the duration of the clinical trial and is the preferred and usual lifestyle of the patient.
  • •ii) Female patients who are surgically sterile (e.g. status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months.
  • •iii) Female patients who are premenarche.
  • •c) Male patients (including female partners) do not require contraception.
  • •3AP) Patients must be able to swallow trial tablets whole.
  • •4AP) Patients, as assessed by the Investigator, must be able to appropriately receive and store IMP, and be able to read, understand, and complete the eDiary.
  • •5AP) Investigator believes that the patient is willing and able to adhere to all protocol requirements.

排除标准

  • •Current exclusion criteria as of 02/04/2024:
  • •Rollover Patients:
  • •1R) Discontinued from the KVD900-301 trial for reasons of non-compliance, withdrawal of consent, or safety.
  • •2R) Presence of any safety concerns that would preclude participation in the open-label trial as determined by the investigator.
  • •Non-Rollover Patients:
  • •1NR) Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1-inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
  • •2NR) A clinically significant history of poor response to bradykinin receptor 2 (BR2) blocker, C1-INH therapy or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
  • •3NR) Use of attenuated androgens (e.g. stanozolol, danazol, oxandrolone, methyltestosterone, testosterone), or anti-fibrinolytics (e.g. tranexamic acid) within 28 days prior to the Enrollment Visit.
  • •4NR) Use of angiotensin-converting enzyme (ACE) inhibitors within 7 days prior to the Enrollment Visit.
  • •5NR) Any estrogen-containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Enrollment Visit.
  • •6NR) Inadequate organ function, including but not limited to:
  • •a) Alanine aminotransferase (ALT) >2x ULN
  • •b) Aspartate aminotransferase (AST) >2x ULN
  • •c) Bilirubin direct >1.25x ULN
  • •d) International normalized ratio (INR) >1.2
  • •e) Clinically significant hepatic impairment defined as a Child-Pugh B or C
  • •7NR) Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial.
  • •8NR) History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
  • •9NR) Known hypersensitivity to KVD900 or to any of the excipients.
  • •10NR) Participation in any gene therapy treatment or trial for HAE.
  • •11NR) Participation in any interventional investigational clinical trial, including an investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of the investigational drug prior to the Enrollment Visit.
  • •12NR) Any pregnant or breastfeeding patient.
  • •Previous exclusion criteria:
  • •1. Discontinued from the KVD900-301 trial for reasons of non-compliance, withdrawal of consent, or safety.
  • •2. Presence of any safety concerns that would preclude participation in the open-label trial as determined by the investigator.
  • •3. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
  • •4. A clinically significant history of poor response to bradykinin receptor 2 (BR2) blocker, C1-INH therapy, or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
  • •5. Use of attenuated androgens (e.g., stanozolol, danazol, oxandrolone, methyltestosterone, testosterone), or anti-fibrinolytics (e.g., tranexamic acid) within 28 days prior to the Enrollment Visit.
  • •6. Use of ACE inhibitors within 7 days prior to the Enrollment Visit.
  • •7. Any estrogen-containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Enrollment Visit.
  • •8. Inadequate organ functio

研究者

相似试验

进行中（未招募）
1 期
ong-term safety of apraglutide in short bowel syndromeMedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersshort bowel syndrome
EUCTR2020-005513-41-DEVectivBio AG154
进行中（未招募）
1 期
ong-term safety of apraglutide in short bowel syndromeshort bowel syndromeMedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2020-005513-41-FRVectivBio AG154
招募中
3 期
Long-term safety of apraglutide in short bowel syndromeshort bowel syndrome
2023-510389-28-00VectivBio AG101
进行中（未招募）
1 期
ong-term safety of apraglutide in short bowel syndromeshort bowel syndromeMedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2020-005513-41-DKVectivBio AG154
招募中
3 期
Apraglutide Open-Label Phase 3 Extension Trialshort bowel syndrome and intestinal failure (SBS-IF)
JPRN-jRCT2031220255Akinori Kashiyama12